antipyrine has been researched along with Apoplexy in 63 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to explore how butylphthalide and edaravone promote healing in acute stroke, drawing on relevant data, literature, clinical experience, and personal concepts." | 9.41 | Clinical Efficacy and Short-Term Prognosis of Butylphthalide and Sodium Chloride Injection Compared to Edaravone in the Treatment of Patients with Acute Stroke. ( Wang, X; Yang, D; Zhang, J; Zhang, M, 2023) |
| "Systematic review and meta-analysis of randomized controlled trials and observational studies comparing edaravone to placebo in adult patients with ischemic stroke." | 9.22 | Edaravone for acute ischemic stroke - Systematic review with meta-analysis. ( Afreixo, V; Fidalgo, M; Gregório, H; Gregório, T; Magalhães, P; Ricardo Pires, J; Viseu, I, 2022) |
| "A randomized, double-blind, placebo-controlled study was performed to prospectively evaluate the effects of edaravone on acute diabetic stroke patients admitted to our hospital within 24 h of stroke onset." | 9.22 | Edaravone offers neuroprotection for acute diabetic stroke patients. ( Chen, X; Zheng, J, 2016) |
| "Two new neuro-protective agents, Edaravone and Citicoline were recently found to be beneficial in acute ischemic stroke (AIS)." | 9.16 | Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS). ( Bansal, KK; Goel, D; Mitta, M; Puri, P, 2012) |
| "The aim of the present study was to investigate whether administration of edaravone during t-PA infusion can enhance early recanalization in acute stroke patients." | 9.16 | Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients--a preliminary study. ( Aoki, J; Iguchi, Y; Inoue, T; Kimura, K; Kobayashi, K; Sakai, K; Sakamoto, Y; Shibazaki, K, 2012) |
| "Edaravone treatment reduced the volume of the infarct and improved neurological deficits during the subacute period, especially in the small-vessel occlusion strokes." | 9.15 | Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke. ( Nakase, T; Suzuki, A; Yoshioka, S, 2011) |
| "Edaravone treatment for up to 14 days suppresses the progression of disuse muscle atrophy and improves leg locomotor function to a greater extent than shorter-term treatment in acute stroke patients." | 9.14 | Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study. ( Higashi, Y; Kondo, H; Metoki, N; Moriwaki, H; Naritomi, H; Nishimura, H; Oda, T; Oe, H; Saito, K; Tanahashi, N; Tanaka, K; Terayama, Y; Yamamoto, Y; Yuasa, H, 2010) |
| "We conducted a multicenter randomized parallel-group open-label trial of edaravone intravenously and a control drug, sodium ozagrel (ozagrel), a thromboxane A(2) synthase inhibitor, intravenously in acute noncardioembolic ischemic stroke." | 9.14 | Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). ( Kobayashi, S; Saito, I; Shinohara, Y; Uchiyama, S, 2009) |
| "The efficacy of hyperbaric oxygen (HBO) therapy combined with intravenous edaravone (free radical scavenger) administration was prospectively investigated in patients with acute embolic stroke involving the anterior cerebral circulation." | 9.12 | Hyperbaric oxygen combined with intravenous edaravone for treatment of acute embolic stroke: a pilot clinical trial. ( Imai, K; Izumoto, H; Kunieda, T; Mori, T; Takabatake, N; Watanabe, M, 2006) |
| "Edaravone can reduce the rate of death or long-term disability significantly for acute ischemic stroke (AIS) (RR = 0." | 8.91 | Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials. ( Cui, X; Li, J; Liu, M; Yang, J; Zhang, C; Zhang, J, 2015) |
| " Hence, although the data in this review show an effective treatment trend of edaravone for acute ischaemic stroke, further large, high-quality trials are required to confirm this trend." | 8.87 | Edaravone for acute ischaemic stroke. ( Feng, S; Li, J; Li, W; Liu, M; Wu, B; Yang, Q; Yuan, W; Zhang, S, 2011) |
| "Edaravone may be a useful neuroprotective agent to treat the > 15 million victims worldwide who are devastated by stroke annually." | 8.86 | A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? ( Lapchak, PA, 2010) |
| "Among patients treated with edaravone alone and edaravone + tPA, the mean reduction in the National Institutes of Health Stroke Scale from baseline to 3 months after the onset was 2." | 7.88 | Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2018) |
| "Edaravone is widely used to treat acute ischemic stroke (AIS) within 24 hours of onset." | 7.85 | Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2017) |
| " The free-radical scavenger edaravone is used in combination with the recombinant tissue plasminogen activator alteplase to treat acute ischemic stroke." | 7.81 | The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model. ( Ishii, H; Sakamoto, K; Sato, T; Yamamoto, J; Yamashita, T, 2015) |
| "Fourteen hybrids (10a-g, 11a-g) of 3-n-butylphthalide (NBP) and edaravone (Eda) analogues have been designed and synthesized as potential anti-ischemic stroke agents." | 7.81 | Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents. ( Hua, K; Huang, Z; Ji, H; Sheng, X; Wang, X; Xu, J; Yang, C; Zhang, Y, 2015) |
| "We investigated whether edaravone could improve early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator (rtPA)." | 7.80 | Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator. ( Fushimi, K; Horiguchi, H; Inokuchi, R; Matsubara, T; Nakajima, S; Wada, T; Yahagi, N; Yasunaga, H, 2014) |
| "Edaravone, a potent antioxidant, may improve thrombolytic therapy because it benefits ischemic stroke patients on its own and mitigates adverse effects of tissue plasminogen activator (tPA) in preclinical models." | 7.80 | Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke. ( Abe, K; Chan, PH; Dunn, RS; Kuan, CY; Li, Y; Lindquist, DM; Morozov, YM; Rakic, P; Sun, YY; Yang, D, 2014) |
| "One hundred twenty-nine consecutive patients who were admitted to our 5 hospital groups and who received intravenous tPA within 3 hours of stroke onset between January 2010 and December 2011 were divided into 2 groups by age (<80 years of age [younger group] and >80 years of age [older group]) and by treatment with or without edaravone." | 7.79 | Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. ( Abe, K; Deguchi, K; Ikeda, Y; Inoue, S; Kashihara, K; Kawada, S; Kiriyama, H; Kono, S; Kurata, T; Manabe, Y; Morimoto, N; Narai, H; Takao, Y; Takehisa, Y; Yamashita, T, 2013) |
| "A novel free radical scavenger, edaravone, has been demonstrated to exert a neuroprotective effect and improve outcomes in acute ischemic stroke, but there have been few clinical studies." | 7.79 | Investigation of effect of edaravone on ischemic stroke. ( Adachi, H; Ishibashi, A; Yoshitake, Y, 2013) |
| "A free radical scavenger, edaravone, which has been used for the treatment of ischemic stroke, was reported to cause acute kidney injury (AKI) as a fatal adverse event." | 7.79 | Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry. ( Hayashi, K; Kamouchi, M; Kitazono, T; Kiyohara, Y; Minematsu, K; Sakai, H, 2013) |
| "A male patient with rheumatoid arthritis (RA) developed acute stroke and was treated with the free radical scavenger, edaravone." | 7.73 | Edaravone inhibits the disease activity in rheumatoid arthritis. ( Arii, K; Hashimoto, K; Ikeda, Y; Kumon, Y; Suehiro, T, 2006) |
| "In acute ischemic stroke patients, combination therapy using tPA with edaravone appears to be a reasonable strategy for diminishing the negative effects of tPA." | 7.73 | Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model. ( Harada, T; Kano, T; Katayama, Y, 2005) |
| "This study aimed to explore how butylphthalide and edaravone promote healing in acute stroke, drawing on relevant data, literature, clinical experience, and personal concepts." | 5.41 | Clinical Efficacy and Short-Term Prognosis of Butylphthalide and Sodium Chloride Injection Compared to Edaravone in the Treatment of Patients with Acute Stroke. ( Wang, X; Yang, D; Zhang, J; Zhang, M, 2023) |
| "Edaravone is a free radical scavenger, and borneol has shown anti-inflammatory effect." | 5.40 | The synergetic effect of edaravone and borneol in the rat model of ischemic stroke. ( Gao, LY; Hua, Y; Liao, GY; Luo, CX; Sun, WX; Tang, Y; Wu, HY; Yang, SB; Zhang, ZP; Zhou, QG; Zhu, DY, 2014) |
| " No adverse events were observed." | 5.38 | Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger. ( Baba, H; Hashizume, M; Kuwashiro, T; Lee, S; Nagata, H; Nanishi, E; Sugimori, H, 2012) |
| "Diabetic rats exposed to 2-hr middle cerebral artery occlusion (MCAO) and 22 hr of reperfusion significantly had increased infarct, oedema volume and functional neurological deficits as compared to sham-operated rats." | 5.38 | Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. ( Sharma, SS; Srinivasan, K, 2012) |
| "Edaravone was originally developed as a potent free radical scavenger and, since 2001, has been widely used to treat AIS in Japan." | 5.36 | Edaravone: a new therapeutic approach for the treatment of acute stroke. ( Arimura, S; Hashiguchi, T; Kawahara, K; Kikuchi, K; Kuramoto, T; Maenosono, R; Maruyama, I; Matsuda, F; Mera, K; Miura, N; Miyagi, N; Morimoto, Y; Ohno, Y; Oyama, Y; Shigemori, M; Shrestha, B; Tada, K; Takenouchi, K; Tancharoen, S; Uchikado, H; Yoshida, Y; Yoshinaga, N, 2010) |
| "Edaravone is a lipophilic drug with multiple mechanisms of action." | 5.35 | The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. ( Lapchak, PA; Zivin, JA, 2009) |
| "Systematic review and meta-analysis of randomized controlled trials and observational studies comparing edaravone to placebo in adult patients with ischemic stroke." | 5.22 | Edaravone for acute ischemic stroke - Systematic review with meta-analysis. ( Afreixo, V; Fidalgo, M; Gregório, H; Gregório, T; Magalhães, P; Ricardo Pires, J; Viseu, I, 2022) |
| "A randomized, double-blind, placebo-controlled study was performed to prospectively evaluate the effects of edaravone on acute diabetic stroke patients admitted to our hospital within 24 h of stroke onset." | 5.22 | Edaravone offers neuroprotection for acute diabetic stroke patients. ( Chen, X; Zheng, J, 2016) |
| "MCI-186 (edaravone) is a free radical scavenger approved in Japan since 2001 for the treatment of patients with acute ischemic stroke within 24 h from the onset of symptoms." | 5.17 | Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. ( Dippel, DW; Ford, GA; Kaste, M; Murayama, S; Tatlisumak, T; Walters, MR, 2013) |
| "To identify prognostic factors affecting outcomes at 90 days after stroke from the viewpoint of recovery patterns, we enrolled 660 patients from the Edaravone and Argatroban Stroke Therapy for Acute Ischemic Stroke study database." | 5.17 | Prognostic significance of smoking in patients with acute ischemic stroke within 3 months of onset. ( Kumagai, N; Nagao, T; Okuhara, Y; Origasa, H; Takekawa, H; Yamaguchi, T, 2013) |
| "We evaluated the influence of smoking on 90-day outcomes after acute atherothrombotic stroke in 292 Japanese men extracted from the database of the Edaravone and Argatroban Stroke Therapy for Acute Ischemic Stroke randomized parallel-group trial that tested the safety and efficacy of edaravone and argatroban therapy in 814 patients in 2004-2008." | 5.17 | Effects of smoking on outcomes after acute atherothrombotic stroke in Japanese men. ( Fujimoto, Y; Iiyama, T; Kawanishi, Y; Kumagai, N; Okuhara, Y; Origasa, H; Takekawa, H; Yamaguchi, T, 2013) |
| "Two new neuro-protective agents, Edaravone and Citicoline were recently found to be beneficial in acute ischemic stroke (AIS)." | 5.16 | Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS). ( Bansal, KK; Goel, D; Mitta, M; Puri, P, 2012) |
| "The aim of the present study was to investigate whether administration of edaravone during t-PA infusion can enhance early recanalization in acute stroke patients." | 5.16 | Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients--a preliminary study. ( Aoki, J; Iguchi, Y; Inoue, T; Kimura, K; Kobayashi, K; Sakai, K; Sakamoto, Y; Shibazaki, K, 2012) |
| "Edaravone treatment reduced the volume of the infarct and improved neurological deficits during the subacute period, especially in the small-vessel occlusion strokes." | 5.15 | Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke. ( Nakase, T; Suzuki, A; Yoshioka, S, 2011) |
| "We conducted a multicenter randomized parallel-group open-label trial of edaravone intravenously and a control drug, sodium ozagrel (ozagrel), a thromboxane A(2) synthase inhibitor, intravenously in acute noncardioembolic ischemic stroke." | 5.14 | Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). ( Kobayashi, S; Saito, I; Shinohara, Y; Uchiyama, S, 2009) |
| "Edaravone treatment for up to 14 days suppresses the progression of disuse muscle atrophy and improves leg locomotor function to a greater extent than shorter-term treatment in acute stroke patients." | 5.14 | Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study. ( Higashi, Y; Kondo, H; Metoki, N; Moriwaki, H; Naritomi, H; Nishimura, H; Oda, T; Oe, H; Saito, K; Tanahashi, N; Tanaka, K; Terayama, Y; Yamamoto, Y; Yuasa, H, 2010) |
| "The efficacy of hyperbaric oxygen (HBO) therapy combined with intravenous edaravone (free radical scavenger) administration was prospectively investigated in patients with acute embolic stroke involving the anterior cerebral circulation." | 5.12 | Hyperbaric oxygen combined with intravenous edaravone for treatment of acute embolic stroke: a pilot clinical trial. ( Imai, K; Izumoto, H; Kunieda, T; Mori, T; Takabatake, N; Watanabe, M, 2006) |
| "Radical scavenger compounds (such as Ebselen and Edaravone) are under clinical investigation as a therapeutic approach against stroke." | 4.91 | Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2. ( Braunersreuther, V; Carbone, F; Mach, F; Montecucco, F; Teixeira, PC; Vuilleumier, N, 2015) |
| "Edaravone can reduce the rate of death or long-term disability significantly for acute ischemic stroke (AIS) (RR = 0." | 4.91 | Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials. ( Cui, X; Li, J; Liu, M; Yang, J; Zhang, C; Zhang, J, 2015) |
| "Outcome of efficacy of therapies for acute ischemic stroke are as followed: All of the therapies mentioned above yielded results a more effective result than placebo, Sodium ozagrel (RR 3." | 4.90 | Efficacy and safety of therapies for acute ischemic stroke in China: a network meta-analysis of 13289 patients from 145 randomized controlled trials. ( Chen, X; Ma, B; Shi, J; Sun, H; Yang, B, 2014) |
| "Edaravone was originally developed as a potent free radical scavenger, and has been widely used to treat acute ischemic stroke in Japan since 2001." | 4.89 | The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease. ( Kikuchi, K; Morioka, M; Murai, Y; Takeshige, N; Tanaka, E; Tancharoen, S; Yoshitomi, M, 2013) |
| " Hence, although the data in this review show an effective treatment trend of edaravone for acute ischaemic stroke, further large, high-quality trials are required to confirm this trend." | 4.87 | Edaravone for acute ischaemic stroke. ( Feng, S; Li, J; Li, W; Liu, M; Wu, B; Yang, Q; Yuan, W; Zhang, S, 2011) |
| "Edaravone may be a useful neuroprotective agent to treat the > 15 million victims worldwide who are devastated by stroke annually." | 4.86 | A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? ( Lapchak, PA, 2010) |
| "A free radical scavenger Edaravone is the first clinical drug for neuroprotection in the world which has been used from 2001 in most ischemic stroke patients in Japan, and is especially useful in thrombolytic therapy with tissue plasminogen activator (tPA)." | 4.84 | [Neuroprotective therapy for ischemic stroke with free radical scavenger and gene-stem cell therapy]. ( Abe, K, 2008) |
| " Four compounds with free radical scavenging activity (tirilazad, ebselen, edaravone) or free radical trapping properties (NXY-059) have been examined in experimental models of stroke and evaluated clinically as neuroprotective agents." | 4.82 | Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. ( Ashwood, T; Green, AR, 2005) |
| " Only three drugs, nicaravene, ebselen and edaravone, all radical scavengers, were judged effective by small-sized trials with a wide therapeutic window, 48-72 hours after stroke, in Japan." | 4.81 | [Neuroprotective therapy for the treatment of acute ischemic stroke]. ( Naritomi, H, 2001) |
| "Among patients treated with edaravone alone and edaravone + tPA, the mean reduction in the National Institutes of Health Stroke Scale from baseline to 3 months after the onset was 2." | 3.88 | Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2018) |
| "Edaravone is widely used to treat acute ischemic stroke (AIS) within 24 hours of onset." | 3.85 | Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2017) |
| "Fourteen hybrids (10a-g, 11a-g) of 3-n-butylphthalide (NBP) and edaravone (Eda) analogues have been designed and synthesized as potential anti-ischemic stroke agents." | 3.81 | Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents. ( Hua, K; Huang, Z; Ji, H; Sheng, X; Wang, X; Xu, J; Yang, C; Zhang, Y, 2015) |
| " The free-radical scavenger edaravone is used in combination with the recombinant tissue plasminogen activator alteplase to treat acute ischemic stroke." | 3.81 | The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model. ( Ishii, H; Sakamoto, K; Sato, T; Yamamoto, J; Yamashita, T, 2015) |
| " Previous studies have demonstrated that the free radical scavenger edaravone may prevent neuronal injury and brain edema after ICH." | 3.81 | The radical scavenger edaravone improves neurologic function and perihematomal glucose metabolism after acute intracerebral hemorrhage. ( Cui, D; Liang, S; Shang, H; Yang, D; Zhang, W; Zhao, W, 2015) |
| "We investigated whether edaravone could improve early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator (rtPA)." | 3.80 | Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator. ( Fushimi, K; Horiguchi, H; Inokuchi, R; Matsubara, T; Nakajima, S; Wada, T; Yahagi, N; Yasunaga, H, 2014) |
| "Edaravone, a potent antioxidant, may improve thrombolytic therapy because it benefits ischemic stroke patients on its own and mitigates adverse effects of tissue plasminogen activator (tPA) in preclinical models." | 3.80 | Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke. ( Abe, K; Chan, PH; Dunn, RS; Kuan, CY; Li, Y; Lindquist, DM; Morozov, YM; Rakic, P; Sun, YY; Yang, D, 2014) |
| "One hundred twenty-nine consecutive patients who were admitted to our 5 hospital groups and who received intravenous tPA within 3 hours of stroke onset between January 2010 and December 2011 were divided into 2 groups by age (<80 years of age [younger group] and >80 years of age [older group]) and by treatment with or without edaravone." | 3.79 | Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. ( Abe, K; Deguchi, K; Ikeda, Y; Inoue, S; Kashihara, K; Kawada, S; Kiriyama, H; Kono, S; Kurata, T; Manabe, Y; Morimoto, N; Narai, H; Takao, Y; Takehisa, Y; Yamashita, T, 2013) |
| "A novel free radical scavenger, edaravone, has been demonstrated to exert a neuroprotective effect and improve outcomes in acute ischemic stroke, but there have been few clinical studies." | 3.79 | Investigation of effect of edaravone on ischemic stroke. ( Adachi, H; Ishibashi, A; Yoshitake, Y, 2013) |
| "A free radical scavenger, edaravone, which has been used for the treatment of ischemic stroke, was reported to cause acute kidney injury (AKI) as a fatal adverse event." | 3.79 | Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry. ( Hayashi, K; Kamouchi, M; Kitazono, T; Kiyohara, Y; Minematsu, K; Sakai, H, 2013) |
| "Edaravone, a drug for treating acute ischemic stroke, has been reported to provoke acute renal disorders." | 3.75 | Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone. ( Hishida, A, 2009) |
| " The authors compared CBF imaging using flow sensitive alternating inversion recovery (FAIR)-MRI and (14)C-Iodoantipyrine (IAP)-autoradiography in a mouse model of acute stroke." | 3.74 | A flow sensitive alternating inversion recovery (FAIR)-MRI protocol to measure hemispheric cerebral blood flow in a mouse stroke model. ( Dirnagl, U; Endres, M; Gertz, K; Leithner, C; Lindauer, U; Prass, K; Priller, J; Royl, G; Schröck, H; Steinbrink, J; Villringer, A, 2008) |
| "A retrospective review was carried out of 207 Japanese patients with acute stroke who developed renal disorders on edaravone treatment." | 3.74 | Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. ( Hishida, A, 2007) |
| "In acute ischemic stroke patients, combination therapy using tPA with edaravone appears to be a reasonable strategy for diminishing the negative effects of tPA." | 3.73 | Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model. ( Harada, T; Kano, T; Katayama, Y, 2005) |
| "A male patient with rheumatoid arthritis (RA) developed acute stroke and was treated with the free radical scavenger, edaravone." | 3.73 | Edaravone inhibits the disease activity in rheumatoid arthritis. ( Arii, K; Hashimoto, K; Ikeda, Y; Kumon, Y; Suehiro, T, 2006) |
| "In the last few decades, medical treatment for stroke has made progress greatly." | 2.53 | [History and current status of medical treatment for stroke]. ( Yagita, Y, 2016) |
| "Edaravone was approved in Japan for the treatment of acute brain infarction within 24 h after onset in April, 2001." | 2.41 | [Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent]. ( Tanaka, M, 2002) |
| "Rat transient middle cerebral artery occlusion (MCAO) model was established." | 1.43 | Possible Mechanism of Therapeutic Effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model. ( Chen, J; Ding, WS; Ding, XS; Liu, XF; Shen, HC; Shen, LH; Sheng, YF; Ye, M, 2016) |
| "Edaravone is a free radical scavenger, and borneol has shown anti-inflammatory effect." | 1.40 | The synergetic effect of edaravone and borneol in the rat model of ischemic stroke. ( Gao, LY; Hua, Y; Liao, GY; Luo, CX; Sun, WX; Tang, Y; Wu, HY; Yang, SB; Zhang, ZP; Zhou, QG; Zhu, DY, 2014) |
| "Diabetic rats exposed to 2-hr middle cerebral artery occlusion (MCAO) and 22 hr of reperfusion significantly had increased infarct, oedema volume and functional neurological deficits as compared to sham-operated rats." | 1.38 | Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. ( Sharma, SS; Srinivasan, K, 2012) |
| " No adverse events were observed." | 1.38 | Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger. ( Baba, H; Hashizume, M; Kuwashiro, T; Lee, S; Nagata, H; Nanishi, E; Sugimori, H, 2012) |
| "Stroke is an enormous public health problem with an imperative need for more effective therapy." | 1.37 | Translational stroke research of the combination of thrombolysis and antioxidant therapy. ( Amaro, S; Chamorro, Á, 2011) |
| "Edaravone was originally developed as a potent free radical scavenger and, since 2001, has been widely used to treat AIS in Japan." | 1.36 | Edaravone: a new therapeutic approach for the treatment of acute stroke. ( Arimura, S; Hashiguchi, T; Kawahara, K; Kikuchi, K; Kuramoto, T; Maenosono, R; Maruyama, I; Matsuda, F; Mera, K; Miura, N; Miyagi, N; Morimoto, Y; Ohno, Y; Oyama, Y; Shigemori, M; Shrestha, B; Tada, K; Takenouchi, K; Tancharoen, S; Uchikado, H; Yoshida, Y; Yoshinaga, N, 2010) |
| "Edaravone is a lipophilic drug with multiple mechanisms of action." | 1.35 | The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. ( Lapchak, PA; Zivin, JA, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (33.33) | 29.6817 |
| 2010's | 39 (61.90) | 24.3611 |
| 2020's | 3 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Fidalgo, M | 1 |
| Ricardo Pires, J | 1 |
| Viseu, I | 1 |
| Magalhães, P | 1 |
| Gregório, H | 1 |
| Afreixo, V | 1 |
| Gregório, T | 1 |
| Yang, D | 3 |
| Zhang, M | 1 |
| Wang, X | 2 |
| Zhang, J | 2 |
| Shi, X | 1 |
| Ohta, Y | 1 |
| Nakano, Y | 1 |
| Liu, X | 1 |
| Tadokoro, K | 1 |
| Feng, T | 1 |
| Nomura, E | 1 |
| Tsunoda, K | 1 |
| Sasaki, R | 1 |
| Matsumoto, N | 1 |
| Osakada, Y | 1 |
| Bian, Y | 1 |
| Bian, Z | 1 |
| Omote, Y | 1 |
| Takemoto, M | 1 |
| Hishikawa, N | 1 |
| Yamashita, T | 3 |
| Abe, K | 4 |
| Tanahashi, N | 4 |
| Yamaguchi, T | 4 |
| Awano, H | 2 |
| Matsuda, H | 2 |
| Kono, S | 1 |
| Deguchi, K | 1 |
| Morimoto, N | 1 |
| Kurata, T | 1 |
| Ikeda, Y | 2 |
| Narai, H | 1 |
| Manabe, Y | 1 |
| Takao, Y | 1 |
| Kawada, S | 1 |
| Kashihara, K | 1 |
| Takehisa, Y | 1 |
| Inoue, S | 1 |
| Kiriyama, H | 1 |
| Kapoor, S | 1 |
| Mitta, M | 1 |
| Goel, D | 1 |
| Bansal, KK | 1 |
| Puri, P | 1 |
| Kamouchi, M | 1 |
| Sakai, H | 1 |
| Kiyohara, Y | 1 |
| Minematsu, K | 1 |
| Hayashi, K | 1 |
| Kitazono, T | 1 |
| Kikuchi, K | 2 |
| Tancharoen, S | 2 |
| Takeshige, N | 1 |
| Yoshitomi, M | 1 |
| Morioka, M | 1 |
| Murai, Y | 1 |
| Tanaka, E | 1 |
| Yang, J | 1 |
| Cui, X | 1 |
| Li, J | 2 |
| Zhang, C | 1 |
| Liu, M | 2 |
| Kumagai, N | 2 |
| Okuhara, Y | 2 |
| Iiyama, T | 1 |
| Fujimoto, Y | 1 |
| Takekawa, H | 2 |
| Origasa, H | 2 |
| Kawanishi, Y | 1 |
| Kaste, M | 1 |
| Murayama, S | 1 |
| Ford, GA | 1 |
| Dippel, DW | 1 |
| Walters, MR | 1 |
| Tatlisumak, T | 1 |
| Ishibashi, A | 1 |
| Yoshitake, Y | 1 |
| Adachi, H | 1 |
| Connell, BJ | 1 |
| Saleh, MC | 1 |
| Kucukkaya, I | 1 |
| Abd-El-Aziz, AS | 1 |
| Khan, BV | 1 |
| Saleh, TM | 1 |
| Yang, B | 1 |
| Shi, J | 1 |
| Chen, X | 2 |
| Ma, B | 1 |
| Sun, H | 1 |
| Carbone, F | 1 |
| Teixeira, PC | 1 |
| Braunersreuther, V | 1 |
| Mach, F | 1 |
| Vuilleumier, N | 1 |
| Montecucco, F | 1 |
| Hashimoto, T | 1 |
| Shibata, K | 1 |
| Ohata, H | 1 |
| Hasumi, K | 1 |
| Honda, K | 1 |
| Sun, YY | 1 |
| Morozov, YM | 1 |
| Li, Y | 1 |
| Dunn, RS | 1 |
| Rakic, P | 1 |
| Chan, PH | 1 |
| Lindquist, DM | 1 |
| Kuan, CY | 1 |
| Wu, HY | 1 |
| Tang, Y | 1 |
| Gao, LY | 1 |
| Sun, WX | 1 |
| Hua, Y | 1 |
| Yang, SB | 1 |
| Zhang, ZP | 1 |
| Liao, GY | 1 |
| Zhou, QG | 1 |
| Luo, CX | 1 |
| Zhu, DY | 1 |
| Wada, T | 1 |
| Yasunaga, H | 1 |
| Inokuchi, R | 1 |
| Horiguchi, H | 1 |
| Fushimi, K | 1 |
| Matsubara, T | 1 |
| Nakajima, S | 1 |
| Yahagi, N | 1 |
| Shang, H | 1 |
| Cui, D | 1 |
| Liang, S | 1 |
| Zhang, W | 2 |
| Zhao, W | 1 |
| Aoyama, Y | 1 |
| Ohta, S | 1 |
| Sakaki, S | 1 |
| Nishizawa, S | 1 |
| Fujita, T | 1 |
| Suzuki, Y | 2 |
| Inatomi, Y | 1 |
| Yonehara, T | 1 |
| Hirano, T | 1 |
| Lu, HC | 2 |
| Chang, WJ | 1 |
| Kuan, YH | 1 |
| Huang, AC | 2 |
| Shyu, BC | 2 |
| Sato, T | 1 |
| Sakamoto, K | 1 |
| Ishii, H | 1 |
| Yamamoto, J | 1 |
| Sheng, X | 1 |
| Hua, K | 1 |
| Yang, C | 1 |
| Ji, H | 1 |
| Xu, J | 1 |
| Huang, Z | 1 |
| Zhang, Y | 1 |
| Zheng, J | 1 |
| Shen, LH | 1 |
| Chen, J | 1 |
| Shen, HC | 1 |
| Ye, M | 1 |
| Liu, XF | 1 |
| Ding, WS | 1 |
| Sheng, YF | 1 |
| Ding, XS | 1 |
| Yagita, Y | 1 |
| Lapchak, PA | 2 |
| Zivin, JA | 1 |
| Hishida, A | 2 |
| Shinohara, Y | 2 |
| Saito, I | 1 |
| Kobayashi, S | 1 |
| Uchiyama, S | 1 |
| Hughes, JL | 1 |
| Beech, JS | 1 |
| Jones, PS | 1 |
| Wang, D | 1 |
| Menon, DK | 1 |
| Baron, JC | 1 |
| Kawahara, K | 1 |
| Miyagi, N | 1 |
| Uchikado, H | 1 |
| Kuramoto, T | 1 |
| Morimoto, Y | 1 |
| Miura, N | 1 |
| Takenouchi, K | 1 |
| Oyama, Y | 1 |
| Shrestha, B | 1 |
| Matsuda, F | 1 |
| Yoshida, Y | 1 |
| Arimura, S | 1 |
| Mera, K | 1 |
| Tada, K | 1 |
| Yoshinaga, N | 1 |
| Maenosono, R | 1 |
| Ohno, Y | 1 |
| Hashiguchi, T | 1 |
| Maruyama, I | 1 |
| Shigemori, M | 1 |
| Naritomi, H | 2 |
| Moriwaki, H | 1 |
| Metoki, N | 1 |
| Nishimura, H | 1 |
| Higashi, Y | 1 |
| Yamamoto, Y | 1 |
| Yuasa, H | 1 |
| Oe, H | 1 |
| Tanaka, K | 1 |
| Saito, K | 1 |
| Terayama, Y | 1 |
| Oda, T | 1 |
| Kondo, H | 1 |
| Baba, H | 1 |
| Sugimori, H | 1 |
| Nanishi, E | 1 |
| Nagata, H | 1 |
| Lee, S | 1 |
| Kuwashiro, T | 1 |
| Hashizume, M | 1 |
| Nakase, T | 1 |
| Yoshioka, S | 1 |
| Suzuki, A | 1 |
| Amaro, S | 1 |
| Chamorro, Á | 1 |
| Srinivasan, K | 1 |
| Sharma, SS | 1 |
| Kimura, K | 1 |
| Aoki, J | 1 |
| Sakamoto, Y | 1 |
| Kobayashi, K | 1 |
| Sakai, K | 1 |
| Inoue, T | 1 |
| Iguchi, Y | 1 |
| Shibazaki, K | 1 |
| Feng, S | 1 |
| Yang, Q | 1 |
| Li, W | 1 |
| Yuan, W | 1 |
| Zhang, S | 1 |
| Wu, B | 1 |
| Nagao, T | 1 |
| Carmichael, ST | 1 |
| Tatsukawa, K | 1 |
| Katsman, D | 1 |
| Tsuyuguchi, N | 1 |
| Kornblum, HI | 1 |
| Green, AR | 1 |
| Ashwood, T | 1 |
| Kano, T | 1 |
| Harada, T | 1 |
| Katayama, Y | 1 |
| Arii, K | 1 |
| Kumon, Y | 1 |
| Suehiro, T | 1 |
| Hashimoto, K | 1 |
| Ferrington, L | 1 |
| Kirilly, E | 1 |
| McBean, DE | 1 |
| Olverman, HJ | 1 |
| Bagdy, G | 1 |
| Kelly, PA | 1 |
| Shima, K | 1 |
| Imai, K | 1 |
| Mori, T | 1 |
| Izumoto, H | 1 |
| Takabatake, N | 1 |
| Kunieda, T | 1 |
| Watanabe, M | 1 |
| Koerner, IP | 1 |
| Noppens, R | 1 |
| Grafe, M | 1 |
| Tsai, HJ | 1 |
| Morisseau, C | 1 |
| Luria, A | 1 |
| Hammock, BD | 1 |
| Falck, JR | 1 |
| Alkayed, NJ | 2 |
| Leithner, C | 1 |
| Gertz, K | 1 |
| Schröck, H | 1 |
| Priller, J | 1 |
| Prass, K | 1 |
| Steinbrink, J | 1 |
| Villringer, A | 1 |
| Endres, M | 1 |
| Lindauer, U | 1 |
| Dirnagl, U | 1 |
| Royl, G | 1 |
| Watanabe, T | 1 |
| Tahara, M | 1 |
| Todo, S | 1 |
| Vannucci, SJ | 1 |
| Willing, LB | 1 |
| Goto, S | 1 |
| Brucklacher, RM | 1 |
| Wood, TL | 1 |
| Towfighi, J | 1 |
| Hurn, PD | 1 |
| Simpson, IA | 1 |
| Umemura, K | 1 |
| Tanaka, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIa, Multi-centre, Randomised, Double-blind, Placebo Controlled, Clinical Study Investigating the Safety, Tolerability and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke[NCT00821821] | Phase 2 | 36 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury[NCT03968042] | Phase 2 | 150 participants (Anticipated) | Interventional | 2019-06-30 | Recruiting | ||
| Edaravone-Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) Comparative Post-Marketing Study on Acute Ischemic Stroke[NCT00200356] | Phase 4 | 401 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Randomized, Double Blind Study Assessing the Clinical Efficacy of Combined Treatment With Uric Acid and rtPA Administered Intravenously in Acute Ischemic Stroke Patients Within the First 4.5 Hours of Symptoms Onset[NCT00860366] | Phase 2/Phase 3 | 421 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Multicenter Randomized Open-Label Comparison Study on the Efficacy and Safety of Argatroban Monotherapy With Argatroban-Edaravone Combination Therapy[NCT00153946] | Phase 4 | 814 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Post-Stroke Spasticity[NCT02268461] | 4 participants (Actual) | Interventional | 2014-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The geometric mean values of MCI-186 plasma concentration at the end of the infusion (at 72h) in cohorts 1 and 2 were determined. (NCT00821821)
Timeframe: 72 hours
| Intervention | ng / ml (Geometric Mean) |
|---|---|
| MCI-186 Cohort1 | 391 |
| MCI-186 Cohort2 | 1595 |
Additional Outcome Measures are included in Tables for Serious Adverse Events and Other Adverse Events to report their numbers and frequency. (NCT00821821)
Timeframe: 87days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Deaths | Serious Adverse Events | Other Adverse Events | |
| MCI-186 Cohort1 | 0 | 0 | 12 |
| MCI-186 Cohort2 | 0 | 2 | 10 |
| Placebo Group | 0 | 1 | 10 |
"The Barthel Index of Activities of Daily Living measures functional disability by quantifying patient performance in 10 activities of daily life. These activities can be grouped according to self-care (feeding, grooming, bathing, dressing, bowel and bladder care, and toilet use) and mobility (ambulation, transfers, and stair climbing). 5-point increments are used in scoring, with a maximal score of 100 indicating that a patient is fully independent in physical functioning, and a lowest score of 0 representing a totally dependent bed-ridden state.~The number of patients with 95-100 Barthel Index was evaluated at at 3 months after treatment initiation." (NCT00200356)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Edaravone | 148 |
| Ozagrel | 133 |
The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). (NCT00200356)
Timeframe: Before treatment initiation
| Intervention | scores on a scale (Mean) |
|---|---|
| Edaravone | 3.7 |
| Ozagrel | 3.8 |
The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 1 month after treatment initiation. (NCT00200356)
Timeframe: 1 month
| Intervention | units on a scale (Mean) |
|---|---|
| Edaravone | 3.632 |
| Ozagrel | 3.680 |
The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 14 days after treatment initiation. (NCT00200356)
Timeframe: 14 days
| Intervention | units on a scale (Mean) |
|---|---|
| Edaravone | 4.521 |
| Ozagrel | 4.686 |
The Japan stroke scale (motor function) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from -0.26 (no deficit) to 31.29 (worst). The mean of Japan stroke scale (motor function) score at 3 months after treatment initiation. (NCT00200356)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| Edaravone | 2.507 |
| Ozagrel | 2.927 |
The number of patients with an Modified Rankin Scale score of 0-1 was evaluated at 6 months after treatment initiation. The Modified Rankin Scale has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability. (NCT00200356)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Edaravone | 112 |
| Ozagrel | 108 |
The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 1 month after treatment initiation. (NCT00200356)
Timeframe: 1 month
| Intervention | participants (Number) |
|---|---|
| Edaravone | 117 |
| Ozagrel | 119 |
The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 14 days after treatment initiation. (NCT00200356)
Timeframe: 14 days
| Intervention | participants (Number) |
|---|---|
| Edaravone | 98 |
| Ozagrel | 108 |
The NIH stroke scale is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42(dead). The number of patients with NIH stroke scale score of 0-1 at 3 months after treatment initiation. (NCT00200356)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Edaravone | 135 |
| Ozagrel | 140 |
The number of patients with mRS score of 0-1 (good outcome) at 3 months after treatment initiation. The mRS has 6 items, where 0 = No symptoms at all, 1 = No significant disability despite symptoms, 2 = Slight disability, 3 = Moderate disability, 4 = Moderately severe disability, 5 = Severe disability. The higher scores reflect increased disability. (NCT00200356)
Timeframe: 3 months
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Score(0-1) | 0 | 1 | 2 | 3 | 4 | 5 | Death | |
| Edaravone | 109 | 46 | 63 | 37 | 22 | 19 | 2 | 2 |
| Ozagrel | 98 | 39 | 59 | 40 | 29 | 24 | 3 | 1 |
17 reviews available for antipyrine and Apoplexy
| Article | Year |
|---|---|
Edaravone for acute ischemic stroke - Systematic review with meta-analysis.
Topics: Adult; Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Intracranial Hemorrha | 2022 |
Clinical Efficacy and Short-Term Prognosis of Butylphthalide and Sodium Chloride Injection Compared to Edaravone in the Treatment of Patients with Acute Stroke.
Topics: Antipyrine; Edaravone; Humans; Sodium Chloride; Stroke; Treatment Outcome | 2023 |
The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease.
Topics: Animals; Antipyrine; Cardiovascular Diseases; Edaravone; Free Radical Scavengers; Gene Expression; H | 2013 |
Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials.
Topics: Antipyrine; Edaravone; Free Radical Scavengers; Humans; Randomized Controlled Trials as Topic; Strok | 2015 |
Efficacy and safety of therapies for acute ischemic stroke in China: a network meta-analysis of 13289 patients from 145 randomized controlled trials.
Topics: Aged; Antipyrine; Bayes Theorem; China; Coagulants; Drug Therapy, Combination; Edaravone; Fibrinolyt | 2014 |
Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2.
Topics: Animals; Antioxidants; Antipyrine; Azoles; Brain; Edaravone; Humans; Isoindoles; Membrane Glycoprote | 2015 |
[History and current status of medical treatment for stroke].
Topics: Anticoagulants; Antihypertensive Agents; Antipyrine; Edaravone; Fibrinolytic Agents; Humans; Hydroxy | 2016 |
[Thrombolysis by intravenous tissue plasminogen activator (t-PA)--current status and future direction].
Topics: Antipyrine; Aortic Aneurysm, Thoracic; Aortic Dissection; Edaravone; Free Radical Scavengers; Humans | 2009 |
[Neuroprotective therapy for ischemic stroke with free radical scavenger and gene-stem cell therapy].
Topics: Animals; Antipyrine; Cell- and Tissue-Based Therapy; Drug Therapy, Combination; Edaravone; Free Radi | 2008 |
A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?
Topics: Animals; Antipyrine; Brain Ischemia; Drug Evaluation, Preclinical; Edaravone; Free Radical Scavenger | 2010 |
Edaravone for acute ischaemic stroke.
Topics: Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Neuroprotective Agents; Rand | 2011 |
[Neuroprotective therapy for the treatment of acute ischemic stroke].
Topics: Animals; Antioxidants; Antipyrine; Clinical Trials as Topic; Edaravone; Free Radical Scavengers; Hum | 2001 |
[Clinical guidelines for stroke].
Topics: Anticoagulants; Antipyrine; Arginine; Aspirin; Brain Edema; Edaravone; Fibrinolytic Agents; Free Rad | 2004 |
Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.
Topics: Animals; Antioxidants; Antipyrine; Azoles; Benzenesulfonates; Brain Ischemia; Edaravone; Free Radica | 2005 |
[Advanced medical therapy in patients with acute ischemic stroke].
Topics: Administration, Oral; Anticoagulants; Antipyrine; Arginine; Aspirin; Drug Design; Edaravone; Fibrino | 2006 |
[The development of new drugs for acute stroke].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Antioxidants; Antipyrine; Aspirin; Clinical Trial | 2000 |
[Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent].
Topics: Animals; Antipyrine; Brain Edema; Clinical Trials as Topic; Depression, Chemical; Edaravone; Free Ra | 2002 |
10 trials available for antipyrine and Apoplexy
| Article | Year |
|---|---|
Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antipyrine; Brain Ischemia; Cytidi | 2012 |
Effects of smoking on outcomes after acute atherothrombotic stroke in Japanese men.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipyrine; Antithrombins; Arginine; Asian People; Body | 2013 |
Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen.
Topics: Aged; Aged, 80 and over; Antipyrine; Dose-Response Relationship, Drug; Double-Blind Method; Edaravon | 2013 |
Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen.
Topics: Aged; Aged, 80 and over; Antipyrine; Dose-Response Relationship, Drug; Double-Blind Method; Edaravon | 2013 |
Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen.
Topics: Aged; Aged, 80 and over; Antipyrine; Dose-Response Relationship, Drug; Double-Blind Method; Edaravon | 2013 |
Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen.
Topics: Aged; Aged, 80 and over; Antipyrine; Dose-Response Relationship, Drug; Double-Blind Method; Edaravon | 2013 |
Edaravone offers neuroprotection for acute diabetic stroke patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antipyrine; Diabetes Mellitus; Double-Blind Met | 2016 |
Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial).
Topics: Aged; Aged, 80 and over; Antipyrine; Edaravone; Female; Free Radical Scavengers; Humans; Japan; Male | 2009 |
Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study.
Topics: Aged; Antipyrine; Brain Ischemia; Drug Administration Schedule; Edaravone; Female; Free Radical Scav | 2010 |
Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke.
Topics: Activities of Daily Living; Aged; Antipyrine; Brain Infarction; Diffusion Magnetic Resonance Imaging | 2011 |
Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients--a preliminary study.
Topics: Aged; Aged, 80 and over; Antipyrine; Edaravone; Female; Free Radical Scavengers; Humans; Infusions, | 2012 |
Prognostic significance of smoking in patients with acute ischemic stroke within 3 months of onset.
Topics: Aged; Aged, 80 and over; Antipyrine; Arginine; Brain Ischemia; Chi-Square Distribution; Disability E | 2013 |
Hyperbaric oxygen combined with intravenous edaravone for treatment of acute embolic stroke: a pilot clinical trial.
Topics: Acute Disease; Aged; Antipyrine; Combined Modality Therapy; Edaravone; Emergency Medical Services; F | 2006 |
36 other studies available for antipyrine and Apoplexy
| Article | Year |
|---|---|
Neuroprotective effect of CuATSM in mice stroke model by ameliorating oxidative stress.
Topics: Animals; Antipyrine; Brain Ischemia; Infarction, Middle Cerebral Artery; Mice; Neuroprotective Agent | 2021 |
Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes.
Topics: Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Diabetes Mellitus; Disability Evaluation; Disea | 2018 |
Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
Topics: Adult; Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Edaravone; Female; Fibrinolytic Agents; | 2013 |
Neuroprotective effects of edaravone: recent insights.
Topics: Antipyrine; Female; Free Radical Scavengers; Humans; Male; Stroke; Tissue Plasminogen Activator | 2013 |
Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Case-Control Studies; Chi- | 2013 |
Investigation of effect of edaravone on ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Antipyrine; Arginine; Edaravone; Female; Free Radical Scavengers; Hu | 2013 |
UPEI-300, a conjugate of lipoic acid and edaravone, mediates neuroprotection in ischemia/reperfusion.
Topics: Animals; Antipyrine; Brain Ischemia; Cell Hypoxia; Cells, Cultured; Drug Combinations; Male; Neocort | 2014 |
Altered gene expression in an embolic stroke model after thrombolysis with tissue plasminogen activator and Stachybotrys microspora triprenyl phenol-7.
Topics: Animals; Antioxidants; Antipyrine; Benzopyrans; Calgranulin A; Disease Models, Animal; Edaravone; Fr | 2014 |
Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke.
Topics: Animals; Antipyrine; Cell Hypoxia; Disease Models, Animal; Drug Synergism; Edaravone; Humans; Hypoxi | 2014 |
The synergetic effect of edaravone and borneol in the rat model of ischemic stroke.
Topics: Animals; Anti-Inflammatory Agents; Antipyrine; Brain; Brain Ischemia; Camphanes; Cell Survival; Cell | 2014 |
Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator.
Topics: Aged; Aged, 80 and over; Antipyrine; Databases, Factual; Edaravone; Female; Fibrinolytic Agents; Fre | 2014 |
The radical scavenger edaravone improves neurologic function and perihematomal glucose metabolism after acute intracerebral hemorrhage.
Topics: Animals; Antipyrine; Behavior, Animal; Body Water; Brain Edema; Cell Death; Edaravone; Fluorodeoxygl | 2015 |
[Case of spontaneous cervical internal carotid artery dissection with embolic stroke after a job-change].
Topics: Antipyrine; Arginine; Carotid Artery, Internal, Dissection; Diagnosis, Differential; Edaravone; Huma | 2014 |
[Dystypia after ischemic stroke: a disturbance of linguistic processing for Romaji (Romanized Japanese)?].
Topics: Aged; Agraphia; Anticoagulants; Antipyrine; Aphasia; Diffusion Magnetic Resonance Imaging; Drug Ther | 2015 |
A [14C]iodoantipyrine study of inter-regional correlations of neural substrates following central post-stroke pain in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Carbon Radioisotopes; Cerebral Cortex; | 2015 |
The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model.
Topics: Animals; Antipyrine; Disease Models, Animal; Edaravone; Fibrinolysis; Fibrinolytic Agents; Free Radi | 2015 |
Novel hybrids of 3-n-butylphthalide and edaravone: Design, synthesis and evaluations as potential anti-ischemic stroke agents.
Topics: Animals; Antipyrine; Benzofurans; Cell Line; Drug Design; Edaravone; Free Radical Scavengers; Humans | 2015 |
Possible Mechanism of Therapeutic Effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model.
Topics: Animals; Antipyrine; Bone Marrow Cells; Brain Ischemia; Chemokine CXCL12; Disease Models, Animal; Ed | 2016 |
Autoradiographic Measurements of [14C]-Iodoantipyrine in Rat Brain Following Central Post-Stroke Pain.
Topics: Animals; Antipyrine; Brain Mapping; Humans; Pain; Rats; Stroke; Thalamus | 2016 |
Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5).
Topics: Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Cohort Studies; Edaravone; Female; Fibrinolytic | 2017 |
The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator.
Topics: Animals; Antipyrine; Behavior, Animal; Carotid Artery Thrombosis; Disease Models, Animal; Dose-Respo | 2009 |
Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone.
Topics: Acute Kidney Injury; Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Logisti | 2009 |
Mapping selective neuronal loss and microglial activation in the salvaged neocortical penumbra in the rat.
Topics: Animals; Antipyrine; Autoradiography; Brain Mapping; Cerebrospinal Fluid; Cerebrovascular Circulatio | 2010 |
Edaravone: a new therapeutic approach for the treatment of acute stroke.
Topics: Animals; Antipyrine; Edaravone; Free Radical Scavengers; Humans; Neuroprotective Agents; Rats; Strok | 2010 |
Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger.
Topics: Antipyrine; Brain Ischemia; Child; Disability Evaluation; Drug Therapy, Combination; Edaravone; Fema | 2012 |
Translational stroke research of the combination of thrombolysis and antioxidant therapy.
Topics: Antioxidants; Antipyrine; Biomarkers; Edaravone; Fibrinolytic Agents; Humans; Nitrogen Oxides; Oxida | 2011 |
Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress.
Topics: Animals; Antipyrine; Apoptosis; Caspase 12; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2012 |
Evolution of diaschisis in a focal stroke model.
Topics: Animals; Antipyrine; Autoradiography; Blood Flow Velocity; Carbon Radioisotopes; Cerebrovascular Cir | 2004 |
Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model.
Topics: Analysis of Variance; Animals; Antipyrine; Blood Vessels; Cerebral Hemorrhage; Disease Models, Anima | 2005 |
Edaravone inhibits the disease activity in rheumatoid arthritis.
Topics: Antipyrine; Arthritis, Rheumatoid; C-Reactive Protein; Edaravone; Free Radical Scavengers; Humans; M | 2006 |
Persistent cerebrovascular effects of MDMA and acute responses to the drug.
Topics: Acute Disease; Animals; Antipyrine; Autonomic Pathways; Carbon Radioisotopes; Cerebral Arteries; Cer | 2006 |
Soluble epoxide hydrolase: a novel therapeutic target in stroke.
Topics: Adamantane; Animals; Antipyrine; Autoradiography; Blood-Brain Barrier; Blotting, Western; Capillarie | 2007 |
A flow sensitive alternating inversion recovery (FAIR)-MRI protocol to measure hemispheric cerebral blood flow in a mouse stroke model.
Topics: Anesthetics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Autoradiography; Blood Ci | 2008 |
Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance.
Topics: Aged; Aged, 80 and over; Antipyrine; Blood Urea Nitrogen; Creatinine; Edaravone; Female; Free Radica | 2007 |
The novel antioxidant edaravone: from bench to bedside.
Topics: Animals; Anti-Inflammatory Agents; Antipyrine; Drug Evaluation, Preclinical; Edaravone; Free Radical | 2008 |
Experimental stroke in the female diabetic, db/db, mouse.
Topics: Animals; Antipyrine; Autoradiography; Brain; Carbon Radioisotopes; Cerebral Infarction; Cerebrovascu | 2001 |